On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Zenosense, Inc. (ZENO) Early Detection Systems for MRSA/SA & Lung Cancer Proactively Address Massive Global Market

In the case of most progressive illnesses, early detection is key, and this is particularly true for both primary types of lung cancer, NSCLC and SCLC (non-small cell lung cancer and small cell lung cancer), as well as the “Super Bug” known as MRSA (Methicillin-resistant Staphylococcus aureus). MRSA, a kind of robust and highly persistent staph bacterium, is a major, growing concern for hospitals, due in large part to this nasty little bug’s ability to shrug off the most powerful antibiotics available today. Whether a given infection is technically classified as a CA-MRSA (community-acquired) or HA-MRSA (hospital-acquired), the patient end point is invariably a healthcare facility, where the bug may spread and/or lie dormant, posing a serious propagation threat, both for patients and healthcare professionals alike.

Surgical site infection (SSI) continues to be one of the most dangerous postoperative complications, accounting for roughly one third of all HAI’s (hospital-acquired infections) and of that approximately 33% of all HAI’s, nearly 30% are MRSA-positive. MRSA loves to live in the skin and is often hiding in places like the nose, throat and armpits of carriers, making successful decolonization of a given subject extremely tricky. Decolonization requires prolonged treatments, like 5 to 10 days of twice-daily mupirocin in the nose, oral rinsing with 0.2% chlorhexidine three times a day for a week to try and clear the throat, or dilute bleach baths for as long as three months in order to decontaminate carriage sites on the body.

The global HAI testing market ran about $2.2B just two years prior and was recent forecast by Transparency Market Research as topping out around $7.5B in 2019, on a CAGR of roughly 19.3%, making this a huge target for developers and an area of considerable interest for investors as well. The ability to test early and actually prevent more serious/costly issues is an extremely attractive approach for curbing the soaring overall healthcare cost impacts to various economies, making the emergence of detection devices a highly sought-after possibility.

NSCLC lung cancer accounts for as much as 90% of all cases and the global market for just drugs to treat such cancer is on-track to hit around $6.9B by 2019 on a 4.84% CAGR, with the broader therapy market being much larger and on-track to hit around $7.9B by 2020 (GBI Research). With a projected CAGR somewhere in the neighborhood of 6.6%, as new drugs and premium therapies, like second-line and squamous cell treatment continue to emerge and offset generic chemotherapies, the NSCLC treatment market is growing just as fast as a malignant cancer itself. The biggest players like AstraZeneca (NYSE:AZN), Roche (OTCQX: RHHBY) and Merck (NYSE: MRK) will continue to drive the trend towards market segmentation in lung cancer treatment with premium therapies and new drugs, according to GBI Research.

The recent announcement by Zenosense, Inc. (OTCQB: ZENO), which is currently developing two types of electronic nose devices via contract with Zenon Biosystem that continuously monitor for and accurately discriminate hallmark VOCs (volatile organic compounds) of key MRSA and lung cancer biomarkers, that their common stock has been approved by the DTC (Depository Trust Corporation) for DWAC/FAST transfer, makes this small sector up-and-comer even more attractive as a vehicle for investors to tap into these markets. As a developer of detection devices that could save lives while grabbing market share from the treatment end of the game, ZENO’s technology is disruptive and could change the entire MRSA/SA and lung cancer markets on a fundamental level. DWAC/FAST transfer approval of the company’s common stock, using ZENO’s transfer agent, Action Stock Transfer Corporation, confers considerable benefits to shareholders as well. Including rapid brokerage account deposits and withdrawals, elimination of risk associated with handling physical certificates, and the higher liquidity that comes along with such enhanced share accessibility/availability.

Zenosense announced manufacturing of their pre-commercial prototype lung cancer detector early last month (November 4), highlighting key features like the device’s ability to rapidly discriminate against background VOCs in the breath of patients and hone in on the target lung cancer VOC biomarkers. Development partner Zenon Biosystem has come up with some cunning adaptations of the detection pipeline, using molecular sieves in complementary layered and mixed sensor structures, and has developed new metal oxide materials and combinations of metal oxides not found anywhere in the commercially available sensor market today.

Similar breakthroughs in the development of the company’s MRSA detector, including novel biomarker micro-separator sensor technology, has led to testing of a prototype to measure and contrast cultures of MRSA and SA, with a subsequent announcement in late October that the device successfully achieved a sensibility detection rate on cultured headspace in a clinical setting of over 95% during a two-week testing period. The considerable progress ZENO has made in a relatively short time towards commercialization of such highly accurate early detection devices for lung cancer and MRSA/SA could potentially revolutionize the approach to both maladies and saves countless lives.

Given the 224k or so new cases of lung cancer in the U.S. alone each year (around 160k deaths, American Cancer Society) and CDC’s best estimates that 33% of Americans are staph carriers, with 10.8k deaths in the each year from staph, 5.5k of which are MRSA related, there is a massive target market for ZENO’s detection systems.

For more information on Zenosense, please visit: www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered